stockrow
Friday 6 November 2026
Export SMMT’s income statement to Excel — free account
Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
15.85
1.66
+11.70%
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Net income
Summit Therapeutics PLC's net income for fiscal 2025 was −$1.1B, compared with −$221.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$856.1M. Over the past ten years it has ranged from −$1.1B (fiscal 2025) to $6.7M (fiscal 2019) — the current reading is the lowest in ten years. Summit Therapeutics PLC ranks 599th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$1.1B | — |
| FY2024 | −$221.3M | — |
| FY2023 | −$614.9M | — |
| FY2022 | −$78.8M | — |
| FY2021 | −$88.6M | — |
| FY2020 | −$52.7M | — |
| FY2019 | −$29.1M | — |
| FY2019 | $6.7M | — |
| FY2018 | −$26.2M | — |
| FY2018 | −$14.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$215.7M | — |
| Mar 2026 | −$189.4M | — |
| Dec 2025 | −$219.2M | — |
| Sep 2025 | −$231.8M | — |
| 45 more quarters | Free account |
Against its own ten years
Low −$1.1B
High $6.7M
Ten-year median
−$30.7M
Current reading's percentile
7
Net income against peers
| Company | Net income |
|---|---|
| ASND Ascendis Pharma A/S compare | $865.9M |
| HALO Halozyme Therapeutics, Inc. compare | $485.4M |
| JAZZ Jazz Pharmaceuticals PLC compare | $206.0M |
| TECH Bio-Techne Corp compare | $181.9M |
| BMRN BioMarin Pharmaceutical Inc. compare | −$19.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$349.4M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| SMMT Summit Therapeutics PLC | −$856.1M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SMMT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement